Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CRd Induction, ASCT, CRd Consolidation and Lenalidomide Maintenance in Newly Diagnosed Multiple Myeloma
NCT02405364Phase 2Completed
- Sponsor
- Centre hospitalier universitaire de Toulouse
- Start
- Feb 2014
- Primary completion
- Nov 2019
- Modality
- Irreversible Covalent Inhibitors, Reversible Covalent Inhibitors
- Countries
- 1
01
Overview
A Phase 2 trial of carfilzomib in multiple myeloma (MM), sponsored by Centre hospitalier universitaire de Toulouse. Started Feb 2014; status: completed.
02
Drugs
carfilzomib
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT02405364.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02405364.